🔗 Share this article The Global Health Body Sounds Alert Over Acute Shortage of Obesity Jabs Less than one in 10 patients that would benefit from weight-loss injections including Wegovy can access them, warns the World Health Organization as it publishes its first guidance on the therapies. Given more than one billion individuals worldwide currently obese, it is calling for broader and more equitable access to GLP-1 medication. Per estimates, in excess of 2,000,000,000 will be obese by 2030 without intervention. "The new guidance affirms that obesity is a long-term condition that can be treated with comprehensive and lifelong care," said WHO director-general Tedros Adhanom Ghebreyesus. Significant expense, insufficient output, and supply-chain constraints are significant obstacles to universal availability to the jabs that can assist patients in reducing significant body mass, says the body. Skinny Jab Shortage Even under the current most optimistic scenario, the production of such drugs would only suffice for approximately 100 million people – less than 10% of those who need them, per the WHO. The guideline encourages governments and firms to increase access, by strategies such as voluntary licensing. A patent on semaglutide – the main ingredient of the drug Wegovy – is set to lapse in a number of nations in 2026. How Weight-Loss Jabs Operate These medications mimick a natural hormone to reduce digestion speed, curb appetite and enhance feelings of fullness so individuals reduce food intake. Patients typically see weight reduction in the initial weeks of starting on the weekly injections. Research points to patients may put most of the weight back on a year later of stopping the treatment, because their normal hunger return. Being above a healthy weight raises your chance for experiencing diseases, like type 2 diabetes, cardiovascular issues, brain attack, and certain malignancies. Excess weight affects individuals in all nations and was responsible for 3.7 million fatalities worldwide in 2024, according to the WHO.
Less than one in 10 patients that would benefit from weight-loss injections including Wegovy can access them, warns the World Health Organization as it publishes its first guidance on the therapies. Given more than one billion individuals worldwide currently obese, it is calling for broader and more equitable access to GLP-1 medication. Per estimates, in excess of 2,000,000,000 will be obese by 2030 without intervention. "The new guidance affirms that obesity is a long-term condition that can be treated with comprehensive and lifelong care," said WHO director-general Tedros Adhanom Ghebreyesus. Significant expense, insufficient output, and supply-chain constraints are significant obstacles to universal availability to the jabs that can assist patients in reducing significant body mass, says the body. Skinny Jab Shortage Even under the current most optimistic scenario, the production of such drugs would only suffice for approximately 100 million people – less than 10% of those who need them, per the WHO. The guideline encourages governments and firms to increase access, by strategies such as voluntary licensing. A patent on semaglutide – the main ingredient of the drug Wegovy – is set to lapse in a number of nations in 2026. How Weight-Loss Jabs Operate These medications mimick a natural hormone to reduce digestion speed, curb appetite and enhance feelings of fullness so individuals reduce food intake. Patients typically see weight reduction in the initial weeks of starting on the weekly injections. Research points to patients may put most of the weight back on a year later of stopping the treatment, because their normal hunger return. Being above a healthy weight raises your chance for experiencing diseases, like type 2 diabetes, cardiovascular issues, brain attack, and certain malignancies. Excess weight affects individuals in all nations and was responsible for 3.7 million fatalities worldwide in 2024, according to the WHO.